Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 20187229)

1.

Clues to how alpha-synuclein damages neurons in Parkinson's disease.

Sulzer D.

Mov Disord. 2010;25 Suppl 1:S27-31. doi: 10.1002/mds.22639.

PMID:
20187229
2.

Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors.

Wislet-Gendebien S, Visanji NP, Whitehead SN, Marsilio D, Hou W, Figeys D, Fraser PE, Bennett SA, Tandon A.

BMC Neurosci. 2008 Sep 22;9:92. doi: 10.1186/1471-2202-9-92.

3.

Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis.

Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D.

J Neurosci. 2006 Nov 15;26(46):11915-22.

4.

Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.

Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH.

Neurobiol Dis. 2009 Sep;35(3):385-98. doi: 10.1016/j.nbd.2009.05.023. Epub 2009 Jun 6.

PMID:
19505575
5.

Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.

Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM.

J Clin Invest. 2008 Feb;118(2):777-88. doi: 10.1172/JCI32806.

6.

A novel mechanism of interaction between alpha-synuclein and biological membranes.

Kim YS, Laurine E, Woods W, Lee SJ.

J Mol Biol. 2006 Jul 7;360(2):386-97. Epub 2006 May 17.

PMID:
16762368
7.

Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.

Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK.

J Neurosci. 2004 Aug 18;24(33):7400-9.

8.

Generation of a alpha-synuclein-based rat model of Parkinson's disease.

Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P.

Neurobiol Dis. 2008 Apr;30(1):8-18. doi: 10.1016/j.nbd.2007.11.002. Epub 2007 Nov 13.

PMID:
18313315
9.

Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.

Hansen C, Li JY.

Trends Mol Med. 2012 May;18(5):248-55. doi: 10.1016/j.molmed.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503115
10.

Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.

Jo E, Fuller N, Rand RP, St George-Hyslop P, Fraser PE.

J Mol Biol. 2002 Jan 25;315(4):799-807.

PMID:
11812148
11.

Controlling the mass action of alpha-synuclein in Parkinson's disease.

Kim C, Lee SJ.

J Neurochem. 2008 Oct;107(2):303-16. doi: 10.1111/j.1471-4159.2008.05612.x. Epub 2008 Sep 2. Review.

PMID:
18691382
12.

Modulation of alpha-synuclein aggregation by dopamine: a review.

Leong SL, Cappai R, Barnham KJ, Pham CL.

Neurochem Res. 2009 Oct;34(10):1838-46. doi: 10.1007/s11064-009-9986-8. Epub 2009 May 15. Review.

PMID:
19444607
13.

The behavior of alpha-synuclein in neurons.

Fortin DL, Nemani VM, Nakamura K, Edwards RH.

Mov Disord. 2010;25 Suppl 1:S21-6. doi: 10.1002/mds.22722.

PMID:
20187244
14.

Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.

Di Pasquale E, Fantini J, Chahinian H, Maresca M, Taïeb N, Yahi N.

J Mol Biol. 2010 Mar 19;397(1):202-18. doi: 10.1016/j.jmb.2010.01.046. Epub 2010 Jan 28.

PMID:
20114052
15.

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. Epub 2002 Jul 16.

16.

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT.

J Mol Neurosci. 2004;23(1-2):23-34. Review.

PMID:
15126689
17.

Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.

Choong CJ, Say YH.

Neurotoxicology. 2011 Dec;32(6):857-63. doi: 10.1016/j.neuro.2011.05.012. Epub 2011 May 30.

PMID:
21658409
18.

Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.

Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR.

Brain Res. 2000 Jun 2;866(1-2):33-43.

PMID:
10825478
19.

Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein.

Smith DP, Tew DJ, Hill AF, Bottomley SP, Masters CL, Barnham KJ, Cappai R.

Biochemistry. 2008 Feb 5;47(5):1425-34. doi: 10.1021/bi701522m. Epub 2008 Jan 8.

PMID:
18179253
20.

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Gerard M, Deleersnijder A, Daniëls V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V.

J Neurosci. 2010 Feb 17;30(7):2454-63. doi: 10.1523/JNEUROSCI.5983-09.2010.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk